江苏吉贝尔药业股份有限公司 关于获得发明专利的自愿性披露公告

Core Viewpoint - Jiangsu Jibeier Pharmaceutical Co., Ltd. has recently received a patent for an invention related to taxane derivatives, which enhances the quality control of taxane-based anticancer compounds and improves their pharmacological activity while reducing toxicity and side effects [1]. Group 1: Patent Details - The patent pertains to a method for preparing taxane derivatives and their applications in detecting impurities in taxane-based anticancer compounds [1]. - The invention provides reference substances for quality control, which can significantly improve the long-term stability and reduce the toxicity of taxane-based drugs [1]. Group 2: Impact on the Company - The acquisition of this patent reflects the company's core technology and is expected to enhance its intellectual property protection system [1]. - While the patent will not have a significant immediate impact on the company's operations, it is anticipated to promote technological innovation and strengthen the company's core competitiveness [1].